Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up study of GBS-NN/NN2 immune persistence and booster vaccination in a new pregnancy
2024-516364-28-00Phase 3Authorised
- Sponsor
- MinervaX
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label trial of GBS-NN/NN2 vaccine in Streptococcus agalactiae infection (GBS) (2 arms), sponsored by MinervaX. Planned start Dec 2024; status: authorised.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
Streptococcus agalactiae infection (GBS)
Beyond the preview
Go deeper on 2024-516364-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516364-28-00.